382 related articles for article (PubMed ID: 22739108)
1. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model.
Chen L; Fan C; Zhang Y; Bakri M; Dong H; Morisseau C; Maddipati KR; Luo P; Wang CY; Hammock BD; Wang MH
Prostaglandins Other Lipid Mediat; 2013; 104-105():42-8. PubMed ID: 23247129
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.
Liu Y; Lu X; Nguyen S; Olson JL; Webb HK; Kroetz DL
Mol Pharmacol; 2013 Dec; 84(6):925-34. PubMed ID: 24092818
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice.
Chen G; Wang P; Zhao G; Xu G; Gruzdev A; Zeldin DC; Wang DW
Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):63-71. PubMed ID: 21742052
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
[TBL] [Abstract][Full Text] [Related]
6. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy.
Jiang XS; Xiang XY; Chen XM; He JL; Liu T; Gan H; Du XG
Cell Death Dis; 2020 May; 11(5):385. PubMed ID: 32439839
[TBL] [Abstract][Full Text] [Related]
8. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.
Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
11. Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids.
Marowsky A; Meyer I; Erismann-Ebner K; Pellegrini G; Mule N; Arand M
Arch Toxicol; 2017 Nov; 91(11):3571-3585. PubMed ID: 28975360
[TBL] [Abstract][Full Text] [Related]
12. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
[TBL] [Abstract][Full Text] [Related]
13. Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway.
Liang Y; Jing Z; Deng H; Li Z; Zhuang Z; Wang S; Wang Y
Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):70-5. PubMed ID: 25986738
[TBL] [Abstract][Full Text] [Related]
14. Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo.
Liu L; Puri N; Raffaele M; Schragenheim J; Singh SP; Bradbury JA; Bellner L; Vanella L; Zeldin DC; Cao J; Abraham NG
Prostaglandins Other Lipid Mediat; 2018 Sep; 138():1-8. PubMed ID: 30041041
[TBL] [Abstract][Full Text] [Related]
15. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.
Gauthier KM; Olson L; Harder A; Isbell M; Imig JD; Gutterman DD; Falck JR; Campbell WB
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F765-72. PubMed ID: 21753077
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
[TBL] [Abstract][Full Text] [Related]
17. Soluble epoxide hydrolase inhibitor protects against blood-brain barrier dysfunction in a mouse model of type 2 diabetes via the AMPK/HO-1 pathway.
Wu J; Zhao Y; Fan Z; Chen Q; Chen J; Sun Y; Jiang X; Xiao Q
Biochem Biophys Res Commun; 2020 Apr; 524(2):354-359. PubMed ID: 32001002
[TBL] [Abstract][Full Text] [Related]
18. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
19. Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.
Katary MM; Pye C; Elmarakby AA
Prostaglandins Other Lipid Mediat; 2017 Sep; 132():3-11. PubMed ID: 27596333
[TBL] [Abstract][Full Text] [Related]
20. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
